AAV Vectors with U7 snRNA for DMD Exon Skipping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for muscular dystrophies, such as Duchenne and Becker Muscular Dystrophy, are limited, particularly for mutations in exons 6, 7, and 8 of the DMD gene, as existing gene therapy vectors have limited packaging capacity and inefficiencies in restoring the reading frame for dystrophin expression.
Innovation Solution
The use of adeno-associated virus (AAV) vectors carrying nucleic acids with antisense-mediated exon-skipping sequences, specifically targeting exons 6, 7, and 8, to induce skipping of frame-disrupting exons and restore the reading frame for dystrophin protein expression, utilizing U7snRNA as a carrier to target pre-messenger RNA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If existing gene therapy vectors are used to treat muscular dystrophy, then delivery of therapeutic nucleic acids is achieved, but packaging capacity is limited and reading frame restoration is inefficient
Solution Approach 1:
The therapeutic nucleic acid is segmented into multiple functional domains: U7 snRNA scaffold for nuclear targeting, antisense sequences for exon recognition, and splice site blocking sequences for precise splicing modulation. This segmentation allows each component to perform its specific function efficiently while fitting within AAV packaging constraints
Solution Approach 2:
The U7 snRNA acts as an intermediary carrier that delivers antisense sequences to the pre-mRNA in the nucleus. This intermediary mechanism enables precise targeting of splice sites and efficient reading frame restoration without requiring direct delivery of large therapeutic genes by the AAV vector
2Reliability
If antisense-mediated exon skipping is used to restore reading frame, then functional dystrophin expression is achieved, but delivery efficiency and specificity need improvement
Solution Approach 1:
The antisense sequences are designed with specific local properties: complementary base pairing to target exons 6, 7, or 8, flanking splice site sequences for precise binding, and optimal GC content for stable RNA-RNA hybridization. This local quality optimization ensures high-specificity binding to mutant transcripts while maintaining delivery efficiency within AAV constraints
Solution Approach 2:
The invention optimizes parameters including antisense sequence length, GC content, position relative to splice sites, and U7 snRNA scaffold configuration to maximize nuclear delivery efficiency and splice modulation effectiveness while maintaining compatibility with AAV packaging capacity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for increased expression of functional dystrophin protein, improving muscle strength, function, and delaying disease progression, as demonstrated by increased dystrophin protein levels and improved muscle function in clinical trials.
Implementation Method 1
nucleic acids with antisense-mediated exon-skipping sequences, specifically targeting exons 6, 7, and 8, to induce skipping of frame-disrupting exons and restore the reading frame
Implementation Method 2
U7snRNA as a carrier to target pre-messenger RNA
Data Source
AI summary
Products and methods for treating or preventing muscular dystrophies in patients with mutations in any of exons 6, 7, 8, or 9 in their DMD gene are provided. Gene therapy vectors, such as adeno-associated virus (AAV) vectors, and methods of using these vectors to deliver nucleic acids comprising DMD antisense sequences in regulating or restoring expression of transcripts of the DMD gene and a functional form of the dystrophin protein are provided. The products and methods are used for treating, ameliorating and/or preventing muscular dystrophies, such as Duchenne Muscular Dystrophy or Becker Muscular Dystrophy.